In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies
Open Access
- 1 May 2017
- journal article
- research article
- Vol. 20 (5) , 489-496
Abstract
Objective(s): Lung cancer is the main leading cause of cancer death worldwide. Angiogenesis is the main step in proliferation and spreading of tumor cells. Targeting vascular endothelial growth factor (VEGF) is an effective approach for inhibition of cancer angiogenesis. Nanobodies (NBs) are a novel class of antibodies derived from the camel. Unique characteristics of Nbs like their small size and good penetration to tumor tissues makes them promising tools in drug development. Development of NBs targeting both human and mouse VEGF is required for understanding their in vivo functions. Therefore, development of cross-species reactive anti-VEGF Nbs for immunotherapy of lung cancer was the main aim of the current study. Materials and Methods: Here we developed NBs from Camelus dromedarius library with high specificity and binding affinity to both human and mouse VEGF. In vitro and In vivo function of developed NB was evaluated on human endothelial cells and lung epithelial tumor cells (TC-1). Results: A nanobody showed the highest affinity to human and mouse VEGF and potently inhibited VEGF in the ELISA experiment. Anti-VEGF NBs significantly inhibited in vitro human endothelial cell migration through blockade of VEGF (P=0.045). Anti-VEGF NBs also significantly inhibited in vivo TC-1 growth in a dose-dependent manner (P=0.001) and resulted in higher survival rate in the nanobody treated group Conclusion: These findings demonstrate the potential of anti-VEGF NBsin tumor growth inhibition and are promising as novel cancer therapeutic candidate.Keywords
This publication has 33 references indexed in Scilit:
- Mechanisms and regulation of endothelial VEGF receptor signallingNature Reviews Molecular Cell Biology, 2016
- Imaging Cancer Angiogenesis and Metastasis in a Zebrafish Embryo Model2016
- Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobodyMolecular Immunology, 2015
- A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomationThe FASEB Journal, 2014
- The Anti-Tumor Activity of a Neutralizing Nanobody Targeting Leptin Receptor in a Mouse Model of MelanomaPLOS ONE, 2014
- Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted TherapyClinical Cancer Research, 2008
- Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodiesProceedings of the National Academy of Sciences, 2007
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the CombinationBioMed Research International, 2000
- Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassayJournal of Immunological Methods, 1987